Cronos Group Inc

Cronos Group reported record second-quarter 2026 results, with consolidated net revenue of $53 million, up 58% year-over-year, gross profit of $28.5 million, up 96%, and adjusted EBITDA of $13.1 million, an improvement of $11.4 million. The company attributed the growth to higher cannabis flower sales in Israel, Canada, and Germany, as well as higher extract sales in Canada, with gross margin benefiting from favorable mix and seasonally better growing conditions. Cronos also announced that the Israeli Trade Levies Commissioner has opened a new investigation into alleged dumping of medical cannabis imports from Canada, which the company disputes and says it will cooperate with fully. The company ended the quarter with $827 million in cash, cash equivalents, short-term investments, and non-current interest-bearing deposits, and expects to close its acquisition of CanAdelaar in the Netherlands in the second half of 2026.

Cronos Group announced it has appointed ATB Capital Markets Corp., doing business as ATB Cormark, to act as its broker for share repurchases over the facilities of the TSX or other alternative Canadian trading systems, replacing Virtu Canada Corp. The appointment is made under the company's previously announced share repurchase program. Cronos is an innovative global cannabis company with a diverse international brand portfolio including Spinach, PEACE NATURALS, LIT and Lord Jones.

Cronos Group reported first-quarter 2026 net revenue of $45.2 million, a 40% year-over-year increase driven by higher cannabis flower sales in Israel, Canada, and other international markets. Gross profit rose 39% to $19.2 million, while its Canadian brands posted 18% retail sales growth, far outpacing the industry's 2% gain. Despite the strong quarter, Zacks Investment Research assigns Cronos a Zacks Rank of 4, or Sell, citing intense competition from peers such as Aurora Cannabis and Tilray Brands and caution about the pace at which strategic initiatives will translate into sustained earnings growth. The company's shares have risen more than 2% year to date, compared with a nearly 7% decline for the industry.

Cronos Group Inc. announced that shareholders elected all seven director nominees at its annual meeting held on June 18, 2026, with each receiving over 93.6% of votes cast in favor. Shareholders holding 271,828,759 common shares, representing 72.24% of outstanding shares, voted in person or by proxy. An advisory resolution on executive compensation was approved with 99.09% support, and shareholders voted in favor of holding such advisory votes annually. The appointment of Davidson & Company LLP as independent auditor for fiscal 2026 was also approved.

Cronos Group has expanded its share repurchase program after receiving Toronto Stock Exchange approval, allowing the company to buy back up to US$50,000,000 of common shares on both US and Canadian exchanges through May 13, 2027. The cross-listing expansion signals management's capital allocation priorities and view of intrinsic value. The company recently reported first-quarter 2026 revenue of US$45.21 million and net income of US$13.75 million. While the buyback supports the near-term narrative of returning capital, it also raises questions about financial flexibility amid ongoing cash outflows and capital spending.